Delphia Therapeutics
Michael Burke is a seasoned professional in the field of medicinal chemistry, currently serving as the Sr. Director of Chemistry at Delphia Therapeutics since May 2024, focusing on Activation Lethality in cancer research. Prior to this role, Michael held various positions, including Medicinal Chemistry Consultant for Stealth Mode Biotech and Business Owner at Burke Chem Consulting LLC in early 2024. From May 2020 to March 2024, Michael was the Director of Medicinal Chemistry at Ikena Oncology, where extensive responsibilities included managing workflow and overseeing DMPK prosecution. Michael's career commenced with foundational experiences at Bayer, Boehringer Ingelheim, and Blueprint Medicines, where significant contributions to cancer and immunology projects were made. Michael holds an MSc in Organic Chemistry from the University of Calgary and a BScH in Chemistry from Acadia University.
This person is not in any teams
Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.